ASC
The 29th HPC Connection Workshop (HPCC) will be held online at 2pm (CEST) on May 30, 2022, at ISC22 with the theme "The Latest Convergence of AI & HPC." World renowned experts and industry leaders will introduce the latest in the convergence of AI and HPC.
Featured speakers include:
- Jean-Marc Denis, Chief Strategy Officer of SiPearl, will describe new paradigms and challenges in Exascale era with the perspective of the key decisions made for Rhea processor architecture and design. Rhea is built on Arm's Neoverse V1 processor architecture, but it also has 29 RISC-V cores deployed as controllers. Rhea is planned to be deployed in an European Exascale supercomputer in 2023.
- Radoslav Danilak, CEO of Tachyum, will provide an overview of the features and benefits of Tachyum Prodigy, the world’s first Universal Processor. With 128 64-bit CPU cores operating at up to 5.7GHz, Prodigy not only handles general-purpose computing, HPC, and AI workloads on a single chip, it does so with a power budget that's 10 times lower than that of traditional hardware and at one-third the cost.
- Wolfgang Gentzsch, President of UberCloud, will summarize UberCloud’s 10 year achievements and present several customer use cases, and elaborate on UberCloud’s fully automated, portable, self-service, and multi-cloud engineering platform.
- Shu Yin, Assistant Professor at ShanghaiTech University, will share how to optimize HPC applications from the perspective of I/O, and will demonstrate best practices and use cases.
- Weizheng Lu, Tech Lead of Public Computing Center at Renmin University of China, will talk about Jax-Quant-Finance, and the High Performance Quantitative Library which brings HPC, Deep Learning, and Financial Mathematics together to accelerate financial problems time-to-resolution on heterogeneous platforms.
- Longxiang Li, Senior HPC engineer at Inspur Information, will detail the building of data-driven scientific workflows by coupling HPC with machine learning methods and introduce Inspur’s recent achievements in the fields of materials science, CFD, and ocean modeling.
The 29th HPC Connection Workshop Digital 2pm (CEST) May 30, 2022 Online |
Agenda |
Rhea Processor: Overall Strategic Directions and Specifications Jean-Marc Denis Chief Strategy Officer (CSO), SiPearl |
Tachyum Prodigy, The World’s First Universal Processor Radoslav Danilak CEO, Tachyum |
10 Year HPC in the Cloud: From Early Cloud Experiments to a Fully Automated Simulation Multi-Cloud Platform for Complex Engineering Workflows Wolfgang Gentzsch President of UberCloud |
Optimize HPC applications from the I/O perspectives Shu Yin Assistant Professor, ShanghaiTech University |
Jax-Quant-Finance: Bring HPC, Deep Learning and Financials Mathematics together Weizheng Lu Tech Lead of Public Computing Center, Renmin University of China |
Building data-driven scientific workflows with machine learning and HPC applications Longxiang Li Senior HPC engineer, Inspur Information |
Click here to register: http://www.asc-events.net/HPCC/ISC22.php
About HPC Connection Workshop
The HPC Connection Workshop is an international High Performance Computing event organized by the Asia Supercomputer Community and Inspur Information. This event takes place three times a year: during ASC in China, ISC in Germany, and SC in the USA. Top researchers and leading professionals from around the world gather at the workshops to discuss the latest developments and disruptive technologies in AI and supercomputing. Visit ASC's website for highlights and videos of the past events: (http://www.asc-events.org/ ).
View source version on businesswire.com: https://www.businesswire.com/news/home/20220523005035/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 12:31:00 CET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 00:49:00 CET | Press release
‒ Named Most Respected Public Semiconductor Company Achieving $100 Million to $500 Million in Annual Sales ‒ Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom